Drägerwerk AG & Co. KGaA (OTCMKTS:DGWPF – Get Free Report) and Orchestra BioMed (NASDAQ:OBIO – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

This table compares Drägerwerk AG & Co. KGaA and Orchestra BioMed’s net margins, return on equity and return on assets.

This table compares Drägerwerk AG & Co. KGaA and Orchestra BioMed”s revenue, earnings per share and valuation.

Drägerwerk AG & Co. KGaA has higher earnings, but lower revenue than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Drägerwerk AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

13.9% of Drägerwerk AG & Co. KGaA shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

This is a summary of recent ratings and price targets for Drägerwerk AG & Co. KGaA and Orchestra BioMed, as provided by MarketBeat.

Orchestra BioMed has a consensus price target of $13.60, indicating a potential upside of 216.65%. Given Orchestra BioMed’s stronger consensus rating and higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than Drägerwerk AG & Co. KGaA.

Orchestra BioMed beats Drägerwerk AG & Co. KGaA on 6 of the 11 factors compared between the two stocks.

(Get Free Report)

Drägerwerk AG & Co. KGaA operates as a medical and safety technology company worldwide. It develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency medicine, perioperative care, intensive care, and perinatal medicine. The company also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. Its products portfolio includes anesthesia devices and ventilators, thermoregulation equipment, hospitable consumables and accessories, supply units, lights, gas management systems, patient monitoring, software applications, system products, and other services. The company's product portfolio also comprises stationary and mobile gas detection systems, personal protective equipment, and alcohol and drug testing devices. In addition, it offers various training and services, as well as fire training facilities for firefighters. The company was founded in 1889 and is headquartered in Lübeck, Germany. Drägerwerk AG & Co. KGaA operates as a subsidiary of Stefan DrÄGer Gmbh.

(Get Free Report)

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Receive News & Ratings for Drägerwerk AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drägerwerk AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Citigroup Issues Positive Forecast for Vornado Realty Trust (NYSE:VNO) Stock Price

Head-To-Head Contrast: MTN Group (OTCMKTS:MTNOY) & Tele2 (OTCMKTS:TLTZY)